Cancer drugs seem to get more lenient treatment from the U.S. Food and Drug Administration, which has become increasingly intolerant of side effects in drugs that aren't targeting potentially fatal conditions. Once approved, drugmakers can spend less to market new cancer drugs because they don't have to run Super Bowl ads or employ an army of salespeople, as they do when they're trying to sell a sleeping aid or diet pill to millions of patients and their family doctors. Last, Medicare and health insurance companies are willing to pay large sums for new, targeted cancer drugs that are tailored to be as much as 90-percent effective in a specific group of patients.
... area has certainly not been missed," said Bert Hazlett, an analyst at BMO Capital Markets in New ...
NEW YORK -- Pfizer Inc., struggling with fierce competition from makers of generic drugs, announced Monday it will cut 10,000 jobs and close at least five facilities as part of an effort to slash its annual costs by up to $2 billion by the end of next year. The drastic measures by the world's largest drug maker highlight the challenges faced by many pharmaceutical companies recently. In addition to patent expirations, big drug companies are facing a business climate where insurers and other large purchasers of medicines are demanding lower prices and more evidence of products' worth.
...Bert Hazlett, a managing director at BMO Capital Market...
Gen Re exec to plead guilty, aid AIG probe NEW YORK - An executive for Berkshire Hathaway Inc.'s Gen Re insurance unit will plead guilty this week to a criminal charge that he helped rival American International Group Inc. exaggerate its finances and will cooperate in the continuing investigation, his lawyer said Monday.
... to SunTrust Robinson Humphrey analyst Bert Hazlett. * *. Lowe's to open its first Canadian st...
...--(BUSINESS WIRE) . Bert Hazlett, analyst at Robertson Stephens, thinks the...
Pfizer Inc., the world's largest drug maker, said Wednesday it asked U.S. regulators to approve its experimental Sutent medicine for kidney and stomach cancers. The application to the Food and Drug Administration is the first by the New York-based company for a new cancer drug. Sutent attacks tumors by depriving them of their blood supply. Pfizer also is testing Sutent against colon, breast and lung cancer and a rare type of cancer called neuroendocrine tumors.
..."We're thrilled" that Pfizer filed, said Bert Hazlett, an analyst at SunTrust Robinson Humphrey ...
NEW YORK -- Pfizer Inc. said Tuesday it is exploring various options for its nearly $4 billion over-the-counter drug unit, including selling or spinning off the business that includes Listerine mouthwash, Visine eye drops and Lubriderm lotion. The move comes as Pfizer struggles to improve its sales and earnings in the wake of patent losses on several important drugs, sluggish sales of key medicines and an overall more competitive marketplace. Analysts surveyed by Thomson Financial expect only 1 percent earnings growth this year.
...Bert Hazlett, an analyst at Suntrust Robinson Humphrey,...
WASHINGTON - The first inhalable version of insulin won federal approval Friday, giving millions of adult diabetics an alternative to some of the regular injections they now endure. The Food and Drug Administration said the Pfizer Inc. insulin, to be marketed as "Exubera," is the first new way of delivering insulin since the discovery of the hormone in the 1920s.
... patient demand will be significant," said Bert Hazlett, an analyst at Suntrust Robinson Humphrey....
NEW YORK - A patent victory on its biggest selling drug, Lipitor, boosted Pfizer Inc.'s shares nearly 8 percent Monday as a major uncertainty was eliminated, even though other significant challenges remain. Most analysts had expected Pfizer would defeat the challenge to its cholesterol lowering drug from Indian pharmaceutical company Ranbaxy Laboratories Ltd. Still, some investors remained wary of the stock, opting not to risk a negative surprise, analysts said.
...But Bert Hazlett, an analyst at SunTrust Robinson Humphrey ...
NEW YORK - The Food and Drug Administration told Merck & Co. that it requires further safety and efficacy data before it will approve Arcoxia, the successor drug to now defunct pain reliever Vioxx. The news was not unexpected because Merck pulled Vioxx from the market the past month after a study showed it doubled patients' risk of heart attacks and strokes. The two products are in the same class of drugs known as cox-2 inhibitors.
... is a positive that the drug wasn't killed," Bert Hazlett, an analyst at SunTrust Robinson Humphrey....
NEW YORK (AP) - She asks in a sultry voice if you want to know a secret. And when she spills the beans, she is quite explicit. The latest ad for an erectile dysfunction treatment is taking the battle for dominance in the $2 billion market up a notch with its frank description of the medicine's purpose. The Levitra ad, slated to begin airing Thursday, features an attractive brunette saying the drug improves erection quality and how that experience increases her partner's desire to "do this more often.
...Sun Trust Robinson Humphrey analyst Bert Hazlett expects Viagra sales to be flat this year ...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
Hasselblad Ab | Justice May | Ara Parseghian | François Poulet | Montanwerke Brixlegg | programme d'aide aux entreprises | campagnac aveyron | informe pericial de daños | fidelity
